DMAC — DiaMedica Therapeutics Share News
0.000.00%
Last trade - 00:00- $513.37m
- $469.88m
Brief: DiaMedica Therapeutics Says FDA Maintaining Clinical Hold On Remedy2 Trial
Brief: DiaMedica Therapeutics Appoints Julie Daves As Svp, Clinical Development Operations
DiaMedica Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Diamedica Therapeutics Provides A Business Update And Announces Second Quarter 2022 Financial Results
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Diamedica down after stroke therapy trial put on clinical hold
Diamedica drops after FDA places stroke therapy trial on hold
Brief: Diamedica Therapeutics Announced That FDA Has Placed A Clinical Hold On Company's Phase 2/3 Remedy2 Trial
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:28 PM
DiaMedica Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Diamedica Therapeutics Announces First Quarter 2022 Results
DiaMedica Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
DiaMedica Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: DiaMedica Therapeutics Provides A Business Update And Announces Fourth Quarter 2021 Financial Results
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
DiaMedica Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: DiaMedica Therapeutics Reports Q3 2021 Financial Results
DiaMedica Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview